The Eliava International Phage Therapy Center (http://eliavaphagetherapy.com) in Tblisi, Republic of Georgia, provides a comprehensive array of phage therapy services for infections of adults and children, with specialists in Ear Nose and Throat, Urology, Gynecology, surgical infections and Dermatology. The Eliava phage production facility, Eliava BioPreparations, offers several commercial cocktails including Pyo Bacteriophage and Intesti Bacteriophage and Staphylococcal Bacteriophage. The cocktails are regularly updated based on current clinical challenges, utilizing the large collection of bacteria and phages at the institute. Additionally, they can produce a custom cocktail for a specific infection application when needed using their library of phages that have been refined and tested for therapeutic efficacy and new patient specific isolates. The laboratory, Eliava Analytical-Diagnostic Center, specializes in phage susceptibility testing using the Eliava phage library, in addition to other diagnostics. Center physicians often continue to work with foreign doctors to provide products and advice for treating patients in their home country after initial evaluation and treatment in Tblisi.
Phage Therapy Center (https://www.phagetherapycenter.com/pii/PatientServlet?command=static_home) is another well-established clinic in Tblisi, Republic of Georgia. The center routinely treats many types of infections but specializes in the treatment of chronic infections, including chronic UTI, chronic prostatitis, chronic sinusitis and non-healing wounds. The center has full laboratory facilities, commercial phage therapy cocktails and the ability to arrange for personalized cocktails for specific infections when needed.
The Phage Therapy Center is associated with Phage International™ www.phageinternational.com, a US corporation that was formed in July of 2004 to leverage bacteriophage therapy technologies that are produced in Georgia and is engaged in discovery and rediscovery of effective health care technologies developed in Eurasia, in particular phage therapy.
AmpiPhi is an international public biotechnology company focused on the development of bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. The company has a program for emergency IND applications with the FDA for life-threatening antibiotic resistant infections.
The Phage Therapy Unit of the Institute of Immunology and Experimental Therapy (https://www.iitd.pan.wroc.pl/en/OTF/index.html), headquartered in Wroclaw, Poland, opened in 2005 under the regulation of the European Union and treatment is currently possible only under the rules of a therapeutic experiment and in accord with the Declaration of Helsinki, also regulated in Poland by the Medical Profession Act of 5th December 1996. The phage therapy is conducted on an outpatient basis under the protocol of an experimental program: “Experimental phage therapy of drug-resistant bacterial infections, including MRSA infections” approved by an Independent Bioethics Committee. The main center is in Wroclaw but there are satellite Phage Therapy Units in Cracow and Czestochowa, Poland.
The Queen Astrid Hospital in Brussels, Belgium has developed a program under European Union regulations for the treatment of patients with phage therapy based on individually prepared phage cocktails. Phage cocktails for each patient are assembled from a library of approved phages in a “compounding pharmacy” model of indiviual preparation. They primarily specialize in the treatment of burn infections.
Various other entities are developing approaches to identifying and supplying therapeutic phages for potential use in phage therapy. The Center for Phage Technology at Texas A and M University has developed treatments for emergency IND indications. Further phage therapy information is available at the website phage-therapy.org, a useful website curated by Steven T. Abedon PhD.